NCT03204877

Acute Metabolic Effects of Melatonin Treatment

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: University of Aarhus · Academic / Other
• Sex: Male
• Age: 20 Years – 40 Years
• Healthy volunteers: Accepted

Summary

Modern living is associated with an epidemic of type 2 diabetes mellitus (T2DM). Sleep disturbances are strong independent risk factors for incident diabetes. Melatonin has been implicated in regulation of circadian rhythm and sleep, but it is also ascribed anti-oxidative properties and effects on glucose homeostasis. A potential association between melatonin and T2DM has only been addressed in few human physiological studies, but the topic has received renewed interest since genetic-epidemiological studies have pointed to a role for melatonin in the development of the disease. In the current study, the investigators wish to examine whether treatment with synthetic melatonin induces physiological changes that affect the risk of developing type 2 diabetes. Two studies of the physiological effects of melatonin are included in the present protocol. In study A, the investigators will examine the acute effects of Melatonin on insulin secretion and insulin sensitivity using a Botnia clamp and in study B the investigators will examine the potential effects of Melatonin on the incretin response.

Detailed description

Modern living is associated with an epidemic of type 2 diabetes mellitus (T2DM). Sleep disturbances such as insomnia and frequent awakenings are strong independent risk factors for incident diabetes with a magnitude of effect comparable to a family history of diabetes. Melatonin has been implicated in regulation of circadian rhythm and sleep, but it is also ascribed anti-oxidative properties and effects on glucose homeostasis. In pancreatic islets melatonin have dual effects depending on which signaling pathway is activated by receptor binding, thus both inhibitory and stimulatory effects on insulin secretion have been reported. The effect of melatonin on the secretion of gut hormones such as glucagon-like peptide 1 (GLP-1) and influence of melatonin on beta cell sensitivity to gut hormones is largely unknown, but the presence of the melatonin receptor in the gut suggests that it may have a role. A potential association between melatonin and T2DM has only been addressed in few human physiological studies, but the topic has received renewed interest since genetic-epidemiological studies have pointed to a role for melatonin in the development of the disease. Genetic mutations in the melatonin receptor which is predicted to change the physiological effects of melatonin have been found to increase the risk for T2DM. Additionally, low endogenous melatonin production has been linked to T2DM risk. The aim of the present study is to examine whether treatment with synthetic melatonin induces physiological changes that affect the risk of developing type 2 diabetes. Two studies of the physiological effects of melatonin are included in the present protocol: Study A: In order to study the acute effects of melatonin administration in healthy men, the investigators aim for assessing whether: * Melatonin affects the substrate turn-over as evaluated by indirect calorimetry * Melatonin has influence on the ability to secrete insulin as assessed by intravenous glucose tolerance test * Melatonin affects the physiological effects of insulin as assessed by use of the hyperinsulinemic euglycemic clamp * Genetic mutations in the melatonin receptor gene affect the treatment response to melatonin Study B: The investigators aim for examining if melatonin given to healthy men affects the secretion of the glucose-lowering gut hormone glucagon-like peptide 1 (GLP-1) and/or affect the glucose-lowering effects of GLP-1. Specifically, the aim is to assess whether: * Melatonin affects the glucose excursions and insulin secretion during an oral glucose tolerance test * Melatonin affects the secretion of GLP-1 during an oral glucose tolerance test * Melatonin affects the incretin response as assessed by an isoglycemic glucose infusion

Conditions

• Glucose Metabolism Disorders

Interventions

Type	Name	Description
DRUG	Melatonin	Oral capsules
OTHER	Placebo	Oral capsules

Timeline

• Start date: 2017-08-22
• Primary completion: 2019-02-27
• Completion: 2020-02-01
• First posted: 2017-07-02
• Last updated: 2020-03-25

Locations

1 site across 1 country: Denmark